Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D
Department of Medicine, Veterans Administration Medical Center, White River Junction, Vermont, USA.
Am J Gastroenterol. 1998 Apr;93(4):536-41. doi: 10.1111/j.1572-0241.1998.161_b.x.
Periodic endoscopic surveillance is generally recommended for patients with Barrett's esophagus. The optimal follow-up strategy for uncomplicated Barrett's esophagus is controversial, in part because of limited data on the rate of neoplastic progression (through the sequence of metaplasia-dysplasia-carcinoma) during endoscopic surveillance. This study aims to quantify the development of dysplasia in patients with uncomplicated Barrett's esophagus and to explore clinical risk factors associated with the development of dysplastic lesions.
We identified 102 patients with endoscopic evidence of Barrett's esophagus and the presence of specialized columnar epithelium who had received endoscopic surveillance for adenocarcinoma at our medical center between 1970 and 1994. We abstracted endoscopic and histologic data from the medical record. All specimens that showed any degree of atypia (per report) were reexamined in blinded fashion by a team of study pathologists who indicated the grade of dysplasia. Time to first diagnosis of dysplasia was plotted using Kaplan-Meier survival curves, and risk factors for development of dysplasia were assessed using Cox regression.
During 563 patient-yr of endoscopic follow-up, three patients developed adenocarcinoma at least 4 yr after initial diagnosis (one developed adenocarcinoma of the cardia, which was incidentally detected during surveillance for Barrett's esophagus). At some point during follow-up, 19 patients developed new onset, low grade dysplasia and four developed high grade dysplasia. None of the patients who had received antireflux surgery developed dysplasia.
If confirmed by larger follow-up studies, our results suggest that surveillance endoscopy can be safely deferred for at least 2 yr following an initial biopsy that is negative or indeterminate for dysplasia. Adoption of this approach would substantially reduce the cost of surveillance for adenocarcinoma. Future trials should explore the role of antireflux surgery in protecting against neoplastic transformation of Barrett's esophagus.
对于巴雷特食管患者,通常建议进行定期内镜监测。单纯性巴雷特食管的最佳随访策略存在争议,部分原因是内镜监测期间肿瘤进展率(通过化生-异型增生-癌序列)的数据有限。本研究旨在量化单纯性巴雷特食管患者异型增生的发生情况,并探索与发育异常病变发生相关的临床风险因素。
我们确定了102例有巴雷特食管内镜证据且存在特殊柱状上皮的患者,这些患者在1970年至1994年间在我们的医疗中心接受了腺癌的内镜监测。我们从病历中提取了内镜和组织学数据。所有显示任何程度异型性(每份报告)的标本均由一组研究病理学家以盲法重新检查,他们指出异型增生的等级。使用Kaplan-Meier生存曲线绘制首次诊断异型增生的时间,并使用Cox回归评估异型增生发生的风险因素。
在563患者年的内镜随访期间,3例患者在初次诊断至少4年后发生腺癌(1例发生贲门腺癌,在巴雷特食管监测期间偶然发现)。在随访的某个时间点,19例患者出现新发低度异型增生,4例出现高度异型增生。接受抗反流手术的患者均未发生异型增生。
如果更大规模的随访研究证实,我们的结果表明,对于初次活检异型增生为阴性或不确定的患者,监测内镜检查可安全推迟至少2年。采用这种方法将大幅降低腺癌监测的成本。未来的试验应探索抗反流手术在预防巴雷特食管肿瘤转化中的作用。